Biophysical studies on the stability of DNA intrastrand cross-links of transplatin

Biophysical Journal

Volumn 95, Issue 9, 2008, Pages 4361-4371

  Kasparkova, Jana ^a   Marini, Victoria ^a   Bursova, Vendula ^a   Brabec, Viktor ^a,b  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

1,10 PHENANTHROLINE; COPPER COMPLEX; DNA; HELICASE; OLIGODEOXYRIBONUCLEOTIDE; PLATINUM; TRANSPLATIN; CISPLATIN; CROSS LINKING REAGENT;

ARTICLE; BIOCHEMISTRY; BIOPHYSICS; CHEMICAL MODIFICATION; CROSS LINKING; DNA SEQUENCE; GENETIC STABILITY; ISOTHERMAL TITRATION CALORIMETRY; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; THERMODYNAMICS; CALORIMETRY; CHEMISTRY; CONFORMATION; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE;

BASE SEQUENCE; BIOPHYSICAL PROCESSES; CALORIMETRY; CISPLATIN; CROSS-LINKING REAGENTS; DNA; NUCLEIC ACID CONFORMATION; OLIGODEOXYRIBONUCLEOTIDES; THERMODYNAMICS;

EID: 58149171466     PISSN: 00063495     EISSN: 15420086     Source Type: Journal    
DOI: 10.1529/biophysj.108.138909     Document Type: Article

References (57)

1. Rosenberg, B., L. Van Camp, J. E. Trosko, and V. H. Mansour. 1969. Platinum compounds: a new class of potent antitumor agents. Nature. 222:385-386.
2. Vrana, O., V. Brabec, and V. Kleinwächter. 1986. Polarographic studies on the conformation of some platinum complexes: relations to anti-tumour activity. Anticancer Drug Des. 1:95-109.
3. Farrell, N., L. R. Kelland, J. D. Roberts, and M. Van Beusichem. 1992. Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine-L1210 and human tumor panels and studies on their mechanism of action. Cancer Res. 52:5065-5072.
4. Brabec, V., V. Kleinwächter, J. L. Butour, and N. P. Johnson. 1990. Biophysical studies of the modification of DNA by antitumor platinum coordination complexes. Biophys. Chem. 35:129-141.
5. Reedijk, J. 1996. Improved understanding in platinum antitumor chemistry. Chem. Commun. 801-806.
6. Farrell, N. 1996. Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry. In Metal Ions in Biological Systems. A. Sigel and H. Sigel, editors. Marcel Dekker, New York, Basel, Hong Kong. 603-639.
7. Kelland, L. R., S. Y. Sharp, C. F. O. Neill, F. I. Raynaud, P. J. Beale, and I. R. Judson. 1999. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. J. Inorg. Biochem. 77:111-115.
8. Brabec, V. 2002. DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Prog. Nucleic Acid Res. Mol. Biol. 71:1-68.
9. Natile, G., and M. Coluccia. 2004. Antitumor active trans-platinum compounds. In Metal Ions in Biological Systems. A. Sigel and H. Sigel, editors. Marcel Dekker, New York, Basel. 209-250.
10. Brabec, V., and J. Kasparkova. 2005. Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs. Drug Resist. Updat. 8:131-146.
11. Jamieson, E. R., and S. J. Lippard. 1999. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 99:2467-2498.
12. Siddik, Z. H. 2003. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265-7279.
13. Wang, D., and S. J. Lippard. 2005. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4:307-320.
14. Brabec, V., and M. Leng. 1993. DNA interstrand cross-links of transdiamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues. Proc. Natl. Acad. Sci. USA. 90:5345-5349.
15. Eastman, A., M. M. Jennerwein, and D. L. Nagel. 1988. Characterization of bifunctional adducts produced in DNA by trans-diamminedichloroplatinum(II). Chem. Biol. Interact. 67:71-80.
16. Eastman, A., and M. A. Barry. 1987. Interaction of trans- diamminedichloroplatinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathione. Biochemistry. 26:3303-3307.
17. Boudvillain, M., R. Dalbies, C. Aussourd, and M. Leng. 1995. Intrastrand cross-links are not formed in the reaction between transplatin and native DNA: relation with the clinical inefficiency of transplatin. Nucleic Acids Res. 23:2381-2388.
18. Leng, M., A. Schwartz, and M. J. Giraud-Panis. 2000. Transplatin-modified oligonucleotides as potential antitumor drugs. In Platinum-Based Drugs in Cancer Therapy. L. R. Kelland and N. P. Farrell, editors. Humana Press, Totowa, New Jersey. 63-85.
19. Giraud-Panis, M.-J., and M. Leng. 2000. Transplatin-modified oligonucleotides as modulators of gene expression. Pharmacol. Ther. 85:175-181.
20. Aupeix-Scheidler, K., S. Chabas, L. Bidou, J.-P. Rousset, M. Leng, and J.-J. Toulme. 2000. Inhibition of in vitro and ex vivo translation by a transplatin-modified oligo(2′-O-methylribonucleotide) directed against the HIV-1 gag-pol frameshift signal. Nucleic Acids Res. 28:438-445.
21. 3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts. Biochemistry. 42:792-800.
22. Brabec, V., K. Neplechova, J. Kasparkova, and N. Farrell. 2000. Steric control of DNA interstrand cross-link sites of trans platinum complexes: specificity can be dictated by planar nonleaving groups. J. Biol. Inorg. Chem. 5:364-368.
23. Kasparkova, J., V. Marini, Y. Najajreh, D. Gibson, and V. Brabec. 2003. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines. Biochemistry. 42:6321-6332.
24. 3(4-hydroxymethylpyridine)] by tumor suppressor protein p53 and character of DNA adducts of this cytotoxic complex. FEBS J. 273:301-314.
25. Najajreh, Y., J. Kasparkova, V. Marini, D. Gibson, and V. Brabec. 2005. Structural characterization and DNA interactions of new cytotoxic transplatin analogues containing one planar and one nonplanar heterocyclic amine ligand. J. Biol. Inorg. Chem. 10:722-731.
26. Comess, K. M., C. E. Costello, and S. J. Lippard. 1990. Identification and characterization of a novel linkage isomerization in the reaction of trans-diamminedichloroplatinum(II) with 5′-d(TCTACGCGTTCT). Biochemistry. 29:2102-2110.
27. Brabec, V., M. Sip, and M. Leng. 1993. DNA conformational distortion produced by site-specific interstrand cross-link of trans- diamminedichloroplatinum(II). Biochemistry. 32:11676-11681.
28. Brabec, V., J. Reedijk, and M. Leng. 1992. Sequence-dependent distortions induced in DNA by monofunctional platinum(II) binding. Biochemistry. 31:12397-12402.
29. Yoon, C., M. D. Kuwabara, R. Law, R. Wall, and D. S. Sigman. 1988. Sequence-dependent variability of DNA structure. J. Biol. Chem. 263: 8458-8463.
30. Schwartz, A., L. Marrot, and M. Leng. 1989. Conformation of DNA modified at a d(GG) or a d(AG) site by the antitumor drug cisdiamminedichloroplatinum(II) . Biochemistry. 28:7975-7978.
31. Bailly, C., D. Gentle, F. Hamy, M. Purcell, and M. J. Waring. 1994. Localized chemical reactivity in DNA associated with the sequence-specific bis intercalation of echinomycin. Biochem. J. 300:165-173.
32. Ross, S. A., and C. J. Burrows. 1996. Cytosine-specific chemical probing of DNA using bromide and monoperoxysulfate. Nucleic Acids Res. 24:5062-5063.
33. Bailly, C., and M. J. Waring. 1997. Diethylpyrocarbonate and osmium tetroxide as probes for drug-induced changes in DNA conformation in vitro. In Drug-DNA Interaction Protocols. K. R. Fox, editor. Humana Press, Totowa, New Jersey. 51-79.
34. Hofr, C., N. Farrell, and V. Brabec. 2001. Thermodynamic properties of duplex DNA containing a site-specific d(GpG) intrastrand crosslink formed by an antitumor dinuclear platinum complex. Nucleic Acids Res. 29:2034-2040.
35. Hofr, C., and V. Brabec. 2001. Thermal and thermodynamic properties of duplex DNA containing site-specific interstrand cross-link of antitumor cisplatin or its clinically ineffective trans isomer. J. Biol. Chem. 276:9655-9661.
36. Bursova, V., J. Kasparkova, C. Hofr, and V. Brabec. 2005. Effects of monofunctional adducts of Platinum(II) complexes on thermodynamic stability and energetics of DNA duplexes. Biophys. J. 88:1207-1214.
37. Novakova, O., H. Chen, O. Vrana, A. Rodger, P. J. Sadler, and V. Brabec. 2003. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media. Biochemistry. 42:11544-11554.
38. Hofr, C., and V. Brabec. 2005. Thermal stability and energetics of 15-mer DNA duplex interstrand cross-linked by trans-diamminedichloroplatinum(II). Biopolymers. 77:222-229.
39. Murphy, J. H., and T. L. Trapane. 1996. Concentration and extinction coefficient determination for oligonucleotides and analogs using a general phosphate analysis. Anal. Biochem. 240:273-282.
40. Burstyn, J. N., W. J. HeigerBernays, S. M. Cohen, and S. J. Lippard. 2000. Formation of cis-diamminedichloroplatinum(II) 1,2-intrastrand cross-links on DNA is flanking-sequence independent. Nucleic Acids Res. 28:4237-4243.
41. Intini, F. P., A. Boccarelli, V. C. Francia, C. Pacifico, M. F. Sivo, G. Natile, D. Giordano, P. De Rinaldis, and M. Coluccia. 2004. Platinum complexes with imino ethers or cyclic ligands mimicking imino ethers: synthesis, in vitro antitumor activity, and DNA interaction properties. J. Biol. Inorg. Chem. 9:768-780.
42. Dalbies, R., D. Payet, and M. Leng. 1994. DNA double helix promotes a linkage isomerization reaction in trans-diamminedichloroplatinum(II)- modified DNA. Proc. Natl. Acad. Sci. USA. 91:8147-8151.
43. Sigman, D. S., and C. H. B. Chen. 1990. Chemical nucleases - new reagents in molecular biology. Annu. Rev. Biochem. 59:207-236.
44. Sigman, D. S. 1990. Chemical nucleases. Biochemistry. 29:9097-9105.
45. Nielsen, P. E. 1990. Chemical and photochemical probing of DNA complexes. J. Mol. Recognit. 3:1-24.
46. Kasparkova, J., N. Farrell, and V. Brabec. 2000. Sequence specificity, conformation, and recognition by HMG1 protein of major DNA interstrand cross-links of antitumor dinuclear platinum complexes. J. Biol. Chem. 275:15789-15798.
47. Pilch, D. S., S. U. Dunham, E. R. Jamieson, S. J. Lippard, and K. J. Breslauer. 2000. DNA sequence context modulates the impact of a cisplatin 1,2-d(GpG) intrastrand cross-link an the conformational and thermodynamic properties of duplex DNA. J. Mol. Biol. 296:803-812.
48. Malina, J., C. Hofr, L. Maresca, G. Natile, and V. Brabec. 2000. DNA interactions of antitumor cisplatin analogs containing enantiomeric amine ligands. Biophys. J. 78:2008-2021.
49. Novakova, O., J. Kasparkova, V. Bursova, C. Hofr, M. Vojtiskova, H. Chen, P. J. Sadler, and V. Brabec. 2005. Conformation of DNA modified by monofunctional Ru(II) arene complexes: recognition by DNA-binding proteins and repair. Relationship to cytotoxicity. Chem. Biol. 12:121-129.
50. Comess, K. M., J. N. Burstyn, J. M. Essigmann, and S. J. Lippard. 1992. Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts. Biochemistry. 31:3975-3990.
51. 2]. A concept for activation of the trans geometry in platinum antitumor complexes. Nucleic Acids Res. 31:6450-6460.
52. Moriarity, B., O. Novakova, N. Farrell, V. Brabec, and J. Kasparkova. 2007. 1,2-GG intrastrand cross-link of antitumor dinuclear bifunctional platinum compound with spermidine linker inhibits DNA polymerization more effectively than the cross-link of conventional cisplatin. Arch. Biochem. Biophys. 459:264-272.
53. Coluccia, M., and G. Natile. 2007. Trans-platinum complexes in cancer therapy. Anti-Cancer Agents Med. Chem. 7:111-123.
54. Gee, J. E., I. Robbins, A. C. VanderLaan, J. H. VanBoom, C. Colombier, M. Leng, A. M. Raible, J. S. Nelson, and B. Lebleu. 1998. Assessment of high-affinity hybridization, RNase H cleavage, and covalent linkage in translation arrest by antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 8:103-111.
55. Bancroft, D. P., C. A. Lepre, and S. J. Lippard. 1990. Pt-195 NMR kinetic and mechanistic studies of cis-diamminedichloroplatinum and trans-diamminedichloroplatinum(II) binding to DNA. J. Am. Chem. Soc. 112:6860-6871.
56. Dalbies, R., M. Boudvillain, and M. Leng. 1995. Linkage isomerization reaction of intrastrand cross-links in trans-diamminedichloroplatinum(II) -modified single-stranded oligonucleotides. Nucleic Acids Res. 23:949-953.
57. 3 by an iminoether in transplatin makes an antitumor drug from an inactive compound. Mol. Pharmacol. 58: 1525-1535.